Seth Hetherington, MD
Board of Directors
Dr Seth Hetherington joins APIE Therapeutics, Inc as a member of the Board of Directors. He is currently the Chief Medical Officer at ReViral biopharma with focus on developing transformative antiviral therapies. Prior to joining ReViral, Dr. Hetherington was the Chief Medical Officer at Genocea Biosciences, Cambridge, MA, USA from 2011 through 2018, where he led the clinical development of therapeutic vaccines. Dr. Hetherington served as Senior Vice President of Clinical and Regulatory Affairs at Icagen, Inc. from May 2006 through December 2010. Prior to Icagen, Dr. Hetherington served as Vice President, Clinical Development and Chief Medical Officer at Inhibitex Inc., focusing on the clinical development of biologics against infectious diseases. He held various positions of increasing responsibility in in HIV Clinical Development at GlaxoSmithKline. Dr. Hetherington is an adjunct clinical faculty member at the University of North Carolina School of Medicine and previously held appointments at several leading academic medical centers, including the University of Tennessee, St. Jude Children’s Research Hospital in Memphis and Albany Medical College. Dr. Hetherington earned his B.S. at Yale University and his M.D. at the University of North Carolina, Chapel Hill.
He completed his postgraduate training in pediatrics and pediatric infectious diseases at the University of North Carolina and the University of Minnesota, respectively. Dr. Hetherington has published extensively in medical and scientific literature, and is board certified in both pediatrics and pediatric infectious diseases. He has served as the industry representative to the Vaccines and Related Blood Products Advisory Committee of the FDA, the National Vaccine Advisory Committee of the U.S. Department of Health and Human Services, and several ad hoc review committees of the National Institutes of Health.